Low-Molecular-Weight Heparin in Pediatric Patients

The incidence of thromboembolic events (TEs) in childhood is greatly underestimated. Two age groups account for ∼70% of TEs in childhood: infants and teenagers. There are several predisposing risk factors for newborns such as small vessels, high hematocrit, and a unique neonatal hemostatic system. Central venous lines contribute to 80% of deep vein thrombosis in newborns. Other risk factors for all children are shock syndromes, trauma, surgery, heart and kidney disease, and acquired or hereditary thrombophilias. The best prophylaxis is to recognize, avoid, and remove risk factors if possible. This is particularly relevant in childhood, where risk factors can be found in the majority of TEs. The serious sequelae of TEs (mortality, and short- and long-term morbidity) require therapeutic intervention.

Unfractionated heparin (UFH) has the following disadvantages: age-dependent unpredictable pharmacokinetics, the need for intravenous access for therapy and monitoring, delays in achieving therapeutic ranges, bleeding risk, the risk of heparin-induced thrombocytopenia, and osteoporosis with long-term use.

Oral anticoagulants, in addition to some of these disadvantages, show considerable variation by diet (especially if there is a change from breast to bottle feeding), medication, and intercurrent illness.

Review of case reports and cohort studies on 728 children treated with low-molecular-weight heparin (LMWH) indicate the following advantages over UFH: minimal monitoring, ease of administration (subcutaneous), and possibly equivalent efficacy and safety. Dose recommendations for pediatric patients cannot be directly extrapolated from those for adult patients. If dosages are calculated according to body weight, infants < 3 months (or < 5 kg) need ∼50% more LMWH than older children or adults to reach prophylactic or therapeutic anti-factor Xa levels. Further studies are necessary to address the following: the importance of risk factors, the necessity of screening for hereditary thrombophilia, the efficacy and safety of treatment, and side effects and duration of treatment.

Thromboembolic events (TEs) are considered to be rare in children. However, recent surveys reveal that TEs in children occur more often than suspected. The incidence is greatly underestimated because TEs are usually overlooked. Retrospective surveys in children treated for acute lymphoblastic leukemia with corticosteroids and asparaginase revealed clinically symptomatic TE in only 2 to 12% of patients.[1] However, in prospective studies with routine imaging, the incidence was more than 20%.[2] [3]

The objectives of this article are to update the present knowledge on TEs in children, including incidence, predominant age groups, risk factors, diagnosis, and indications for prophylaxis and therapy; and to discuss the use of low-molecular-weight heparin (LMWH) in children.

KEYWORDS

Low-molecular-weight heparins (LMWHs) - children - thrombosis

REFERENCES

• 1 Nowak-Göttl U, Heinecke A, von Kries R, Nürnberger W, Münchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukemia: impact of concomitant Escherichia coli asparaginase/prednisone administration.  Thromb Res. 2001;  103 165-172
• 2 Mitchell L, Sutor A, Andrew M. Hemostasis in childhood acute lymphoblastic leukemia: coagulopathy induced by disease and treatment.  Semin Thromb Hemost. 1995;  21 390-401
• 3 Mitchell L G. the PARKAA Investigators . A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase.  Cancer. 2003;  97 508-516
• 4 Sutor A H, Weissbach G, Schreiber R, Bruhn H D, Seifried E. Thrombosen im Kindesalter.  Hämostaseologie. 1992;  12 82-93
• 5 van Ommen C H, Heijboer H, Büller H R, Hirasing R A, Heijmans H S, Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands.  J Pediatr. 2001;  139 676-681
• 6 Andrew M, David M, Adams M et al.. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE.  Blood. 1994;  83 1251-1257
• 7 Nowak-Göttl U, von Kries R, Göbel U. Neonatal symptomatic thromboembolism in Germany: two year survey.  Arch Dis Child Fetal Neonatal Ed. 1997;  76 F163-F167
• 8 Sutor A H, Engelhardt W, Mehrain S, Uhl M, Zurborn D H. Anticoagulation in thrombosis of childhood: Present state. In: Sutor AH Anticoagulation in Thrombosis of Childhood-English Summary of the Present State. Stuttgart, Germany; Schattauer 1997: 293-335
• 9 Kurekci A E, Gokce H, Yilmaz E, Akar N. The importance of factor VIII levels in childhood thrombosis.  Thromb Haemost. 2001;  , (suppl):1451 (abst)
• 10 Nowak-Göttl U, Kosch A, Schlegel N. Thromboembolism in newborns, infants and children.  Thromb Haemost. 2001;  86 464-474
• 11 Sutor A H, Uhl M. Diagnosis of thromboembolic disease during infancy and childhood.  Semin Thromb Hemost. 1997;  23 237-246
• 12 Male C, Chait P, Ginsberg J S et al.. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with asparaginase.  Thromb Haemost. 2002;  87 593-598
• 13 Sutor A H. Screening children with thrombosis for thrombophilic proteins. Cui bono?.  J Thromb Haemost. 2003;  1 886-888
• 14 Monagle P, Adams M, Mahoney M et al.. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry.  Pediatr Res. 2000;  47 763-766
• 15 Monagle P, Michelson A D, Bovill E, Andrew M. Antithrombotic therapy in children.  Chest. 2001;  119 344S-370S
• 16 Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry.  Pediatrics. 1995;  96 939-943
• 17 Marzinotto V, Choi M, Massicotte M P, Chan A KC, Andrew M. Post-thrombotic syndrome in children with previous deep vein thrombosis.  Thromb Haemost. 2001;  , (suppl):OC962 (abst)
• 18 Lanthier S, Carmant L, David M, Larbrisseau A, de Veber G. Stroke in children: the coexistence of multiple risk factors predicts poor outcome.  Neurology. 2000;  54 371-378
• 19 deVeber G, Andrew M. Cerebral sinovenous thrombosis in children.  N Engl J Med. 2001;  345 417-423
• 20 Richardson M W, Allen G A, Monahan P E. Thrombosis in children: current perspective and distinct challenges.  Thromb Haemost. 2002;  88 900-911
• 21 Herrmann R, Schmidmaier G, Markl B et al.. Antithrombogenic coating of stents using a biodegradable drug delivery technology.  Thromb Haemost. 1999;  82 51-57
• 22 Klement P, Du Y J, Berry L, Andrew M, Chan A K. Blood-compatible biomaterials by surface coating with a novel antithrombin-heparin covalent complex.  Biomaterials. 2002;  23 527-535
• 23 Sutor A H. Thrombocytosis in childhood.  Semin Thromb Hemost. 1995;  21 330-339
• 24 Chan K W, Kaikov Y, Wadsworth L D. Thrombocytosis in childhood: a survey of 94 patients.  Pediatrics. 1989;  84 1064-1067
• 25 Massicotte P, Julian J, Webber C, Charpentier K. Osteoporosis: a potential complication of long term warfarin therapy.  Thromb Haemost. 1999;  , (suppl):1333a (abst)
• 26 Shaughnessy S G, Young E, Deschamps P, Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria.  Blood. 1995;  86 1368-1373
• 27 Severin T, Sutor A H. Heparin-induced thrombocytopenia in pediatrics.  Semin Thromb Hemost. 2001;  27 293-299
• 28 Schmugge M, Risch L, Huber A R, Benn A, Fischer J E. Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients.  Pediatrics. 2002;  109 , E10 (abst)
• 29 Fareed J, Hoppensteadt D A, Bick R L. An update on heparins at the beginning of the new millennium.  Semin Thromb Hemost. 2000;  26(suppl 1) 5-21
• 30 Weitz J I. Low-molecular-weight heparins.  N Engl J Med. 1997;  337 688-698
• 31 Andrew M, Marzinotto V, Massicotte P et al.. Heparin therapy in pediatric patients: a prospective cohort study.  Pediatr Res. 1994;  35 78-83
• 32 Massicotte P, Adams M, Marzinotto V, Brooker L A, Andrew M. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study.  J Pediatr. 1996;  128 313-318
• 33 Dix D, Andrew M, Marzinotto V et al.. The use of low molecular weight heparin in pediatric patients: a prospective cohort study.  J Pediatr. 2000;  136 439-445
• 34 Kuhle S, Massicotte M P, Andrew M et al.. A dose-finding study of tinzaparin in pediatric patients.  Blood. 2002;  100 279a
• 35 Nohe N, Kurnik K. Niedermolekulare Heparine in der Pädiatrie.  Hämostaseologie. 2001;  21 118-124
• 36 Nohe N, Flemmer A, Rumler R, Praum M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 4 cases.  Eur J Pediatr. 1999;  158 S134-S139
• 37 Massicotte M P, Julian J, Marzinotto V J et al.. Dose finding and pharmacokinetics of prophylactic doses of a low molecular weight heparin (Reviparin™) in pediatric patients.  Thromb Res. 2003;  , (in press)
• 38 Massicotte M P, Julian J A, Gent M et al.. The PROTEKT Study Group: an open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line related thrombotic complications in children: the PROTEKT trial.  Thromb Res. 2003;  , (in press)
• 39 Massicotte M P, Julian J A, Gent M et al.. An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.  Thromb Res. 2003;  , (in press)
• 40 Sutor A H, Massicotte P, Leaker M, Andrew M. Heparin therapy in pediatric patients.  Semin Thromb Hemost. 1997;  23 303-319
• 41 Massicotte M P. Low-molecular-weight heparin therapy in children.  J Pediatr Hematol Oncol. 2001;  23 189-194
• 42 Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.  Thromb Haemost. 2002;  87 163-164
• 43 Andrew M, deVeber G. Pediatric Thromboembolism and Stroke Protocols. Hamilton, BC; Dekker Inc. 1999
• 44 Crowther M A, Berry L R, Monagle P T, Chan A K. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.  Br J Haematol. 2002;  116 178-186
• 45 Albisetti M, Andrew M. Low molecular weight heparin in children.  Eur J Pediatr. 2002;  161 71-77
• 46 Massicotte M P, Chan A KC, deVeber G, Monagle P. Venous thrombosis in children.  J Thromb Haemost. 2003;  , (in press)
• 47 Dimitrakakis C, Papageorgiou P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin.  Haemostasis. 2000;  30 243-248
• 48 Sorensen H T, Johnsen S P, Larsen H, Pedersen L, Nielsen G L, Moller M. Birth outcomes in pregnant women treated with low-molecular-weight heparin.  Acta Obstet Gynaecol Scand. 2000;  79 655-659
• 49 deVeber G, Chan A, Monagle P et al.. Anticoagulation therapy in pediatric patients with sinovenous thrombosis: a cohort study.  Arch Neurol. 1998;  55 1533-1537
• 50 Punzalan R C, Hillery C A, Montgomery R R, Scott C A, Gill J C. Low-molecular-weight heparin in thrombotic disease in children and adolescents.  J Pediatr Hematol Oncol. 2000;  22 137-142
• 51 Dix D, Andrew M, Marzinotto V et al.. The use of low molecular weight heparin in pediatric patients: a prospective cohort study.  J Pediatr. 2000;  136 439-445
• 52 Piquet P, Laporte-Simitsidis S, Mismetti P, Doubine S, Decousus H. Nadroparin (Fraxiparine) in paediatrics. Dosage nomogram validation after cardiac surgery.  Thromb Haemost. 2001;  (suppl) P2325 , (abst)
• 53 Sträter R, Kurnik K, Heller C, Schobess R, Luigs P, Nowak-Göttl U. Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study.  Stroke. 2001;  32 2554-2558
• 54 Hoffmann S, Knoefler R, Lorenz N et al.. Clinical experience with LMWH in pediatric patients.  Thromb Res. 2001;  103 345-353
• 55 Elhasid R, Lanir N, Sharon R et al.. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia.  Blood Coagul Fibrinolysis. 2001;  12 367-370
• 56 Roschitz B, Beitzke A, Gamillscheg A et al.. UHF bolus administration in comparison to subcutaneous low molecular weight heparin in pediatric cardiac catheterization. In: Scharrer I, Schramm W 32nd Hemophilia Symposium. Berlin; Springer 2002: 111-114